Impotentie brengt een constant ongemak met zich mee, net als fysieke en psychologische problemen in uw leven cialis kopen terwijl generieke medicijnen al bewezen en geperfectioneerd zijn

Uroassociates.com

Curriculum Vitae
Susan Jones Kalota, M.D.


License

Arizona Medical License: 20774

Education

1975 - 1980 University of California San Diego – B.S. in Biology
1977 - 1978 Jr.Year Education Abroad Program: Pau & Paris, France
1982 - 1986 Howard University College of Medicine: Washington, D.C. 1986 - 1988 University of California San Diego – Surgery Internship 1988 - 1992 University of California San Diego – Urology Residency Observer at Institute of Urology – London, England
Publications

Parsons, C.L., Boychuk, D., Jones, S.M., Hurst, R. and Callahan, H. – Bladder
surface glycosaminoglycans: an epithelialpermeability barrier. JUrol 143: 139-142 1990. Jones, S.M., Parsons, C.L. and Stein, P. – Prevention of acrolein inducted bladder injury by pentosanpolysulfate, JUrol 143(4): 280A 1990. Jones, S.M., Stein, P.C. and Parsons, C.L. - Prevention of acrolein inducted bladder injury by pentosanpolysulfate, JUrol 148(1) 163 – 166 1990. Jones, S.M. – The Injured Bladder AUA Today. Jones, S.M., Greene, L.F. and Parsons, C.L. – Evaluation of the urologic patient. The Practice of Urology W.W. Norton & Co. New York, NY 1992 Bidar, M., Kalota, S.M. and Kaplan, G.W. – Infantile hypertrophic pyloric stenosis and hydronephrosis: Is there an association? JUrol 150(1) 153-155. Stratasis Small Intestinal Submucosa Tension-Free Sling Case Report JUro
172(4): 1349 – 1350 October 2004.
Presentations

Jones, S.M. and Parson, C.L. – Prevention of acrolein-induced bladder injury
pentosanpolysulfate. AUA 85th Annual Meeting. New Orleans, LA May 1990.
Jones, S.M. The in’s and out’s of GU Bleeding, Presented to Southern California
Chapter of the American Urologic Association Allied. San Diego, CA September 1991. Speaker for Pfizer, Bayer and Ortho-McNeil Alza Pharmaceutical Speaker’s Bureau 1999 – 2001 Nurse Practitioners Annual Convention - San Diego, CA 2000 Private Practice Gynecologist on simple cystitis - San Francisco, CA 2000 Multiple Community Presentations for Physicians and Lay Persons Consortium of Multiple Sclerosis Centers- Atlanta, GA 2009 Gender Specific Concerns in MS: Urologic manifestation of MS In the male patient Consortium of Multiple Sclerosis Centers- San Antonio, TX 2010 Gender Specific Concerns in MS: Urologic manifestation of MS In the male patient
Awards and Honors

1982 - 1984 Academic Achievement Award for academic excellence at Howard
Nomination to AOA Medical Honor Society – V.P. of Gamma American Medical Women’s Association – Scholarship Department of Surgery honorable mention for scholastic Department of Medicine honorable mention for scholastic Ralph C. Kennedy, M.D. Award for highest score in Psychiatry on Merck Manual Award for highest scholastic records
Research Experience
Federal Drug Administration – Gastroenterology and Urology Devices Panel Member - Center for Devices & Radiological Health (CDRH) Office of Device Evaluation (ODE) Division of Reproductive, Abdominal and Radiological Devices (DRARD) Gastroenterology and Renal Devices Branch (GRDB) 2004 - 2008 Stress Incontinence, Study Phase 2, 1998 Urge Incontinence, Study Phase 3B, 8 patients enrolled/27 months long, 1999 Quality of Life Study for Overactive Bladder Phase 4, 18 patients enrolled 8 weeks long. Pharmacia/Upjohn, 2001 Overactive Bladder Study Phase 3B, 6 patients enrolled/12 weeks long/Pharmacia/Upjohn, 2001 Urogenital Symptoms in Post Menopausal Women Study Phase 4, 2001 Phase 4 Overactive Bladder/Pfizer/PPD with Rapid Trials, 2004 Sanofi-Synthelabo BPH Registry, 22 patients enrolled, 2004 Watson Quality of Life Study for Oxytrol in OAB 2004, 33 patients enrolled, 2004 Phase 3/AstraZeneca/ Jupiter/LDL and C-Reaction Protein/Cholesterol, 2004 Pharmatech/ Phase 3/ Advanced Prostate Cancer, 2004 Odyssey Pharmaceuticals/ Phase 4/ Overactive Bladder, 2005 AstraZeneca/ Overactive Bladder/ Phase 3, 2005 Nymox/ Phase 2/ Benign Prostatic Hyperplasia, 2005 Praecis/ INC Research/Prostate Cancer/ Phase 3, 2005 Indevus/ Double-Blind and Open-Label Drug for OAB, 2005 Pfizer/Phase 2/Stress Incontinence/ 2006 Astellas/ Phase 4/OAB pts with Sx’s of BPH/2006 Nymox/ Phase2/ Benign Prostatic hypertrophy/2007 Astellas/ Phase 2/ Male subjects with LUTS and BOO/2007 Solace Therapeutics/An evaluation of the AttnueX Intravesical System in the Management of Female Patients with Stress Urinary Incontinence/2007 AMS/The Prolapse Registry: An Observational Collection of Short- and Long-Term Patient Outcomes Following Use of AMS Surgical Devices for the Repair Of Female Genital Prolapse./2007 Astellas /047 Phase III Double Blind Placebo Controlled/ OAB Study /2008 Astellas/ 049 Phase III Double Blind Placebo Controlled / OAB Study/2008 Uroplasty/ Study of Urgent PC Vs. Sham Effectiveness in Treatment of OAB/ 2008 Astellas/074 Phase III Double Blind, Parallel Group, Placebo Controlled/ OAB Study/2009 Nymox/ Phase III Randomized Parallel-Group Placebo Controlled, Double Blind Clinical Evaluation/Treatment of BPH/2009 Pfizer/ 13Week Single Arm, Open Label, Multicenter Study to Evaluate Refill Adherence And Satisfaction with Fesoterodine Plus “Your Way” Patient Support Plan” in Patients with Symptoms of OAB/2009 Allergan 191622-095/A Multicenter, Double-Blind, Randomized, Placebo- Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment of BOTOX (Botulinum Toxin A) Purified Neurotoxin Complex Followed by a Treatment With Botox as Applicable in Patients with Idiopathic Overactive Bladder and Urinary Incontinence. Allergan 191622.096/ A Multicenter, Long-Term Follow-up Study of Safety and Efficacy of the Safety and Efficacy of Botox (Botulinum Toxin Type-A) Purified Neurotoxin Complex in Patients with Idiopathic Overactive Bladder and Urinary Incontinence. A Randomized, Parallel Arm, Open-Label Trial Comparing Degarelix With Goserelin Plus Anti- Androgen Flare Protection, In Terms Of Prostate Size Reduction In Prostate Cancer Patients Of Intermediate –To- High Risk, Who Require Neoadjuvant Hormone Therapy Prior To Endo (EN3348-303)/ A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of EN3348 (MCC) As Compared With Mitomycin C In The Intravesical Treatment Of Subjects With BCG Recurrent Or Refractory Non-Muscle Invasive Bladder Cancer. Pfizer A0221049/ A 12 Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Multicenter Trial to Evaluate the Efficacy and Safety of Fesoterodine Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder. Ethicon Endo Surgery, Inc (CI-10-0009) Multi-center, prospective, randomized, double-blind, sham-controlled clinical study to evaluate safety and effectiveness of a transcutaneous, high-frequency, amplitude-modulated, non-invasive neuromodulation device on urgency urinary incontinence in subjects with

Professional Affiliations

12/2001 Recertification - Diplomate American Board of Urology
Southern Arizona Urologic Society
Arizona Urologic Society member 1992 – present Western Section of American Urologic Association member 1992 – present American Urologic Association member 1988 – present Health Policy Committee 1999 – 2000 Committee on Women’s Issues in Urology 1999 – 2000 Society of Woman in Urology 1992 – present President 1999 – 2000 President-elect 1998 – 1999 Board of Directors 1997 – 1998 Tucson Society of Woman Physicians 1993 - present Founding President 1993 – 1994 Secretary/Treasurer 1994 – present Pima County Medical Society 1992 – present Secretary/Treasurer 2001 Board of Directors 1999 – 2001 Board of Directors 1996 – 1998 Arizona Medical Association 1999 – present ArMA Committee on Insurance Reform 1999 – 2000 Scientific Advisory Board for Novasys Medical
Practice Experience
Group Practice General Urology- Urological Associates of Southern Arizona, Tucson, AZ 8/1992 – 04/2011 Private Practice General Urology- Arizona Urologic Urology Resident – University of California San Diego General Surgery Internship & Residency – University of California San Diego Urology Research –University of California San Diego. Study in vivo urea movement across treated bladder epithelium and in-vitro urinary bladder transport. Medical Study Tutor – Anatomy, Microbiology and Pathophysiology Quality Assurance Specialists: Developed Quality Assurance Instruction Manual for General Dynamics – Los Angeles, CA Research Associate – University of California San Diego. Department of Community Medicine study of nutrition and prenatal risk factors to pregnancy outcome.

Source: http://www.uroassociates.com/wp-content/uploads/Curriculum-Vitae.sjk-FOR-WEBSITEdocx1.pdf

Product insert_nikp-glimepiride 3mg_20120828

NIKP-GLIMEPIRIDE TABLET 3mg Nichi-Iko unconsciousness. The clinical picture of severe reduced blood sugar level Taking NIKP-GLIMEPIRIDE with food and drink Tell your doctor immediately if you experience any of the following Glimepiride 3mg Alcohol intake may increase or decrease the blood sugar lowering action of symptoms: NIKP-GLIMEPIRIDE in an unpredictable way. Allergic

lcc.ie

LIMERICK COUNTY COUNCIL P L A N N I N G A P P L I C A T I O N S PLANNING APPLICATIONS GRANTED FROM 27/07/2009 TO 31/07/2009 in deciding a planning application the planning authority, in accordance with section 34(3) of the Act, has had regard to submissions or observations recieved in accordance with these Regulations; that it is the responsibility of any person wishing to use the

Copyright © 2010-2014 Online pdf catalog